IDEAYA Biosciences/$IDYA
13:30
03:10
16:45
06:25
20:00
1D1W1MYTD1Y5YMAX
About IDEAYA Biosciences
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
Ticker
$IDYA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
131
ISIN
US45166A1025
Website
IDYA Metrics
BasicAdvanced
$1.9B
-
-$3.61
0.25
-
Price and volume
Market cap
$1.9B
Beta
0.25
52-week high
$44.42
52-week low
$13.45
Average daily volume
1.3M
Financial strength
Current ratio
13.922
Quick ratio
13.62
Long term debt to equity
2.506
Total debt to equity
2.536
Profitability
EBITDA (TTM)
-357.976
Gross margin (TTM)
-4,510.77%
Net profit margin (TTM)
-4,386.90%
Operating margin (TTM)
-5,147.81%
Revenue per employee (TTM)
$50,000
Management effectiveness
Return on assets (TTM)
-21.84%
Return on equity (TTM)
-31.34%
Valuation
Price to revenue (TTM)
265.414
Price to book
1.87
Price to tangible book (TTM)
1.87
Price to free cash flow (TTM)
-6.933
Free cash flow yield (TTM)
-14.42%
Free cash flow per share (TTM)
-315.30%
Growth
Revenue change (TTM)
-54.85%
Earnings per share change (TTM)
79.98%
3-year revenue growth (CAGR)
-39.78%
3-year earnings per share growth (CAGR)
34.61%
What the Analysts think about IDYA
Analyst ratings (Buy, Hold, Sell) for IDEAYA Biosciences stock.
Bulls say / Bears say
IDEAYA Biosciences has a strong financial position with cash, cash equivalents, and marketable securities totaling approximately $1.1 billion as of December 31, 2024, providing sufficient funding for operations into at least 2028. (wcia.com)
The company has initiated early preclinical research programs targeting new solid tumor biomarkers, aiming for multiple development candidate nominations in 2024, which could lead to first-in-class or best-in-class therapeutics. (1stoncology.com)
IDEAYA's collaboration with GSK on the Werner Helicase inhibitor program has progressed, with a $3.0 million milestone earned for IND-enabling studies and potential for up to $465.0 million in additional milestones, indicating strong partnership and future revenue prospects. (1stoncology.com)
IDEAYA reported a net loss of $72.2 million for the first quarter of 2025, reflecting ongoing financial challenges despite a strong cash position. (nasdaq.com)
The biotechnology sector is highly competitive, and IDEAYA has not generated any revenue from commercial products since inception, relying heavily on successful development and approval of its pipeline. (dcf.fm)
Regulatory challenges pose significant risks, as delays in obtaining necessary approvals can lead to increased costs and extended timelines for product development. (dcf.fm)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.
IDYA Financial Performance
Revenues and expenses
IDYA Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for IDEAYA Biosciences stock?
IDEAYA Biosciences (IDYA) has a market cap of $1.9B as of June 20, 2025.
What is the P/E ratio for IDEAYA Biosciences stock?
The price to earnings (P/E) ratio for IDEAYA Biosciences (IDYA) stock is 0 as of June 20, 2025.
Does IDEAYA Biosciences stock pay dividends?
No, IDEAYA Biosciences (IDYA) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next IDEAYA Biosciences dividend payment date?
IDEAYA Biosciences (IDYA) stock does not pay dividends to its shareholders.
What is the beta indicator for IDEAYA Biosciences?
IDEAYA Biosciences (IDYA) has a beta rating of 0.25. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
